

Lipid-Lowering Treatment Selector

Charts reviewed January 2017. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

		ATV/r	DRV/r	LPV/r	EFV	ETV	NVP	RPV	MVC	DTG	RAL	ABC	FTC	3TC	TDF	ZDV	E/C/F/TAF	E/C/F/TDF
Statins	Atorvastatin	↑	↑	↑490%	↓43%	↓37%	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Fluvastatin	↔	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Lovastatin	↑	↑	↑	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Pravastatin	↔	↑81%	↔	↓44%	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Rosuvastatin	↑213%	↑48%	↑107%	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Simvastatin	↑	↑	↑	↓68%	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fibrates	Bezafibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Clofibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Fenofibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Gemfibrozil	↓	↓	↓41%	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Ezetimibe	↑ ^a	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dosage adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity (<2 fold ↑AUC or <50% ↓AUC). No *a priori* dosage adjustment is recommended.

Text Legend

- ↑ Potential increased exposure of the lipid-lowering drug
- ↓ Potential decreased exposure of the lipid-lowering drug
- ↔ No significant effect
- ↑↑ Potential increased exposure of HIV drug
- ↓↓ Potential decreased exposure of HIV drug
- ^a Unboosted atazanavir

Numbers refer to increased or decreased AUC of the lipid-lowering drug as observed in drug-drug interaction studies.